Olanzapine
- Generic Name
- Olanzapine
- Brand Names
- Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N4S
- CAS Number
- 132539-06-1
- Unique Ingredient Identifier
- N7U69T4SZR
- Background
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resemb...
- Indication
Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.
...
- Associated Conditions
- Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression
- Conditions
- Interventions
- First Posted Date
- 2011-02-25
- Last Posted Date
- 2011-02-25
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 68
- Registration Number
- NCT01303601
- Locations
- 🇨🇳
Department of Psychiatry, the First Hospital of China Medical University, Shenyang, Liaoning, China
Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression
- Conditions
- Interventions
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 42
- Registration Number
- NCT01282632
- Locations
- 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 301
- Registration Number
- NCT01234779
Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 34
- Registration Number
- NCT01234454
- Locations
- 🇺🇸
Unc Psychiatry, Chapel Hill, North Carolina, United States
Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2013-07-08
- Lead Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
- Registration Number
- NCT01193166
Antipsychotics and Gene Expression in Soft Tissues
- Conditions
- Interventions
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 16
- Registration Number
- NCT01185743
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents
- First Posted Date
- 2010-08-19
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Children's Hospital of Eastern Ontario
- Target Recruit Count
- 38
- Registration Number
- NCT01184443
- Locations
- 🇨🇦
Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 152
- Registration Number
- NCT01170117
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸Weill Cornell Medical Center, White Plains, New York, United States
🇺🇸New York State Psychiatric Institute, New York, New York, United States
Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2010-07-16
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- University of Bremen
- Target Recruit Count
- 149
- Registration Number
- NCT01164059
- Locations
- 🇩🇪
Klinikum Bremen-Ost gGmbH, Bremen, Germany
🇩🇪Rheinische Kliniken Düsseldorf der Heinrich-Heine-Universität, Düsseldorf, Germany
🇩🇪Privat-Nerven-Klinik Dr. med. Kurt Fontheim, Liebenburg, Germany
Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism
- Conditions
- Interventions
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2010-08-03
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 10
- Registration Number
- NCT01160991
- Locations
- 🇩🇪
Central Institute of Mental Health, Mannheim, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.